Equillium EQ 深 滬
等待開盤 03-26 09:30:00 美东时间
2.06
+0.110
+5.64%
華盛通- 最 高2.06
- 今 開1.95
- 成交量 18.43万股
- 最 低 1.9007
- 昨 收 1.95
- 總市值 1.25亿
- 52周最高 2.70
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 0.27
- 委 比 -21.63%
- 總股本 6089.33万
- 歷史最高 27.05
- 量 比 0.38
- 振 幅 8.17%
- 歷史最低 0.27
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Equillium Q4 EPS $(0.04) Beats $(0.14) Estimate
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.14) by 70.37 percent. This is a 75 percent increase over losses of $(0.16) per share from the same
今天 04:25
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
Equillium, a biotech company, announced financial results for Q4 and FY 2025, highlighting a $35M private placement in March 2026 and plans to initiate a Phase 1 proof-of-mechanism study for EQ504 in mid-2026. The company expects cash to fund operations into 2029. EQ504, an AhR modulator, targets gastrointestinal and inflammatory lung diseases. R&D expenses decreased due to winding down of clinical studies, while the company focuses on advancing ...
03-25 20:05
3 things to look forward to on Monday
U.S. stocks closed lower on Friday and ended lower for a fourth consecutive week as oil sustained higher prices despite efforts to minimize the impact of the war on the commodity sector. The benchmark...
03-21 04:57
Equillium to Participate in the 38th Annual Roth Conference
<p>Equillium, a biotech company developing therapies for severe autoimmune and inflammatory disorders, announced that its management will participate in a fireside chat at the 38th Annual Roth Conference on March 23, 2026. The company’s lead candidate, EQ504, is a potent aryl hydrocarbon receptor modulator with potential for treating gastrointestinal and lung diseases. More information is available on www.equilliumbio.com. For investor inquiries,...
03-18 12:30
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Equillium stock jumps on $35M financing from RA Capital Management
Equillium (EQ) shares rose 13% premarket after the biotechnology firm secured about $35M in new financing to advance its clinical development of EQ504, an investigational AhR modulator intended to tre...
03-13 20:20
Equillium Announces $35 Million Financing with RA Capital Management
<p>Equillium announced a $35 million financing with RA Capital Management to advance EQ504, a potential next-generation treatment for Ulcerative Colitis. The funds, along with existing resources, are expected to support the company through 2029.</p>
03-13 12:00
Equillium COO Christine Zedelmayer Disposes of Common Shares
Equillium COO Christine Zedelmayer Disposes of Common Shares Christine Zedelmayer, Sr. Vice President and COO of Equillium, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologie
03-12 08:12
Equillium COO Christine Zedelmayer Disposes of Common Shares
Equillium COO Christine Zedelmayer Disposes of Common Shares Christine Zedelmayer, Senior Vice President and COO of Equillium, Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technolog
02-24 01:53
Equillium Grants Stock Options to New Employees Under 2024 Inducement Plan
Equillium Grants Stock Options to New Employees Under 2024 Inducement Plan Equillium Inc. announced that its Board of Directors granted inducement awards of nonstatutory stock options to purchase a total of 59,750 shares of common stock to two new employees under the company's 2024 Inducement Plan.
02-03 05:05
